HealthMore in Health→
Biopharma Dealmaking Is Staying Active, but the Era of the Megadeal Looks Weaker
Biopharma mergers and acquisitions remain strong as large drugmakers search for growth ahead of patent expiries, but the biggest transactions appear to be giving way to smaller target hunting.
Key Takeaways
- Biopharma dealmaking remains strong as large companies prepare for patent expiries.
- The standout change is the relative absence of megadeals.
DE
DT Editorial Team··via endpoints.news